Nuvalent (NUVL) Operating Expenses (2020 - 2026)
Nuvalent (NUVL) reported Operating Expenses of $119.4 million for Q1 2026, up 25.94% on a YoY basis from $94.8 million in Q1 2025, and down 69.23% quarter-over-quarter from $388.0 million in Q4 2025.
Nuvalent (NUVL) Operating Expenses (2020 - 2026) Analysis & Trends
Nuvalent has reported Operating Expenses for 7 years, with the latest figure at $119.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 25.94% year-over-year to $119.4 million; the trailing twelve-month figure through Mar 2026 stood at $526.7 million (up 781.74% YoY), and the FY2025 full-year result was $414.3 million, up 2265.98% from the prior year.
- Operating Expenses for Q1 2026 stood at $119.4 million, down from $388.0 million in the prior quarter.
- The five-year high for Operating Expenses was $388.0 million in Q4 2025, with the low at -$176.6 million in Q4 2024.
- Historically, Operating Expenses has averaged $48.5 million across 5 years, with a median of $30.2 million in 2023.
- Annual changes were most pronounced in 2024 — Operating Expenses tumbled 480.21% — and 2025, when it soared 2986.33%.
- Nuvalent's Operating Expenses stood at $29.3 million in 2022, then surged by 58.49% to $46.4 million in 2023, then plunged by 480.21% to -$176.6 million in 2024, then jumped by 319.77% to $388.0 million in 2025, then slumped by 69.23% to $119.4 million in 2026.
- The last three Operating Expenses figures came in at $119.4 million (Q1 2026), $388.0 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -67.40 Mn |
| 10 | Nuvalent | 9.69 Bn | 9.69 Bn | - | 119.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.41 Mn |
| Dec 31, 2025 | 388.02 Mn |
| Sep 30, 2025 | 11.46 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 94.81 Mn |
| Dec 31, 2024 | -176.56 Mn |
| Sep 30, 2024 | 76.33 Mn |
| Jun 30, 2024 | 65.15 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 46.44 Mn |
| Sep 30, 2023 | 38.78 Mn |
| Jun 30, 2023 | 34.06 Mn |
| Mar 31, 2023 | 30.21 Mn |
| Dec 31, 2022 | 29.30 Mn |
| Sep 30, 2022 | 20.39 Mn |
| Jun 30, 2022 | 18.73 Mn |
| Mar 31, 2022 | 17.69 Mn |
| Dec 31, 2021 | 17.38 Mn |
| Sep 30, 2021 | 12.43 Mn |
| Jun 30, 2021 | 9.85 Mn |